584 reports of this reaction
3.0% of all PARICALCITOL reports
#3 most reported adverse reaction
MYOCARDIAL INFARCTION is the #3 most commonly reported adverse reaction for PARICALCITOL, manufactured by AbbVie Inc.. There are 584 FDA adverse event reports linking PARICALCITOL to MYOCARDIAL INFARCTION. This represents approximately 3.0% of all 19,271 adverse event reports for this drug.
Patients taking PARICALCITOL who experience myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYOCARDIAL INFARCTION is a less commonly reported adverse event for PARICALCITOL, but still significant enough to appear in the safety profile.
In addition to myocardial infarction, the following adverse reactions have been reported for PARICALCITOL:
The following drugs have also been linked to myocardial infarction in FDA adverse event reports:
MYOCARDIAL INFARCTION has been reported as an adverse event in 584 FDA reports for PARICALCITOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYOCARDIAL INFARCTION accounts for approximately 3.0% of all adverse event reports for PARICALCITOL, making it one of the most commonly reported side effect.
If you experience myocardial infarction while taking PARICALCITOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.